Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Neoadjuvant Therapy

Background:

• Advanced head and neck squamous cell carcinoma (HNSCC) requires effective neoadjuvant therapies.
• Taxane, platinum, and cetuximab (TPC) is a treatment regimen used for HNSCC.
• Neoadjuvant therapy aims to improve outcomes before definitive treatment.

Purpose of the Study:

• To evaluate the effectiveness of TPC neoadjuvant therapy for advanced HNSCC.
• To assess the correlation between pathologic response to TPC and clinical outcomes.
• To establish standardized criteria for assessing pathologic response in HNSCC.

Main Methods:

• Retrospective cohort study (1990-2023) at Memorial Sloan Kettering Cancer Center.
• Reviewed patients with HNSCC who received TPC/TPF before definitive therapy.
• Assessed radiographic and pathologic response, disease-free survival (DFS), and overall survival (OS).

Main Results:

• TPC achieved a 71% objective response rate (pORR) in the primary tumor and 61% overall.
• Pathologic response (pORR) in the primary tumor was significantly associated with improved DFS and OS.
• Radiographic response was observed in 88% of patients before definitive surgery.

Conclusions:

• TPC is an effective neoadjuvant treatment for advanced HNSCC prior to surgery.
• Pathologic response assessment after neoadjuvant TPC can inform clinical outcomes.
• Standardized pathologic response criteria are proposed for HNSCC neoadjuvant treatment assessment.